Brief: Springworks Therapeutics Announces Positive Topline Results From The Phase 2B Reneu Trial Of Mirdametinib In Nf1-Pn
16/11/2023 11:33
Nov 16 (Reuters) - SpringWorks Therapeutics Inc
SWTX.O :
* SPRINGWORKS THERAPEUTICS ANNOUNCES POSITIVE TOPLINE
RESULTS FROM
THE PHASE 2B RENEU TRIAL OF MIRDAMETINIB IN NF1-PN
* SPRINGWORKS THERAPEUTICS INC: MIRDAMETINIB WAS GENERALLY
WELL
TOLERATED WITH LOW RATES OF GRADE 3+ ADVERSE EVENTS
* SPRINGWORKS THERAPEUTICS INC - CONFIRMED OBJECTIVE
RESPONSE RATE
OF 52% IN PEDIATRIC PATIENTS AND 41% IN ADULT PATIENTS
* SPRINGWORKS THERAPEUTICS INC: ADDITIONAL DATA EXPECTED TO
BE
PRESENTED AT MEDICAL CONFERENCE AND NDA SUBMISSION TO U.S. FDA
PLANNED IN H1 OF 2024
* SPRINGWORKS - MIRDAMETINIB TREATMENT RESULTED IN DEEP,
DURABLE
RESPONSES & SIGNIFICANT IMPROVEMENTS IN KEY SECONDARY
PATIENT-REPORTED OUTCOME MEASURES
Source text for Eikon: ID:nGNX9cmK5w
Further company coverage: SWTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SpringWorks Therapeutics
See all newsBrief: Merck KGaA Completes Acquisition Of Springworks Therapeutics
Brief: Springworks Therapeutics Expects Nirogacestat Decision From European Commission In Q3
Brief: EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With NF1-PN